Obsidian Therapeutics To Present Updated Data In Participants With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Phase 1 Trial, Phase 1/2 Agni-01 Multicenter Trial Of Amsokigene Autoleucel At Society For Immunotherapy Of Cancer
Obsidian Therapeutics, Inc. (NASDAQ:OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today
Obsidian is showing new test results for a melanoma cancer treatment. When a company shares positive trial data, it can signal the medicine is working and moving forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.